Displaying in-EHR Patient Drug Prices Regarding Savings Messages

Key findings:

  1. 80% of surveyed HCPs consider patient affordability when prescribing, and many default to generics rather than attempting to discern each patient’s insurance coverage
  2. Survey respondents reported a potential 60% to 70% decrease in prescribing share after viewing patient prices
  3. Exposure to brand savings offers helped prescribers maintain their original medication choices

Patients’ medication price obstacles have historically been most apparent in the pharmacy, where high out of pocket costs can trigger sticker shock, a request for a different medication or prescription abandonment. In this traditional paradigm, prescribers typically only become aware of patients’ specific struggles with out of pocket (OOP) costs when they receive pharmacy call-backs or observe patient non-adherence.

Indeed, today’s prescribers select medications with limited, if any, information on the OOP cost to specific patients. At best, product formulary data may be provided via a prescriber’s EHR system by means of national-level pricing information displayed as dollar signs or a green-yellow-red color scheme.

But the days of expecting healthcare professionals (HCPs) to prescribe while wearing “drug price blinders” may be coming to an end. Instead, new initiatives promise to bring patient-specific, current affordability information directly to the prescriber in the EHR. Leading manifestations of this movement include many focused on the concept of “real time benefit check” (RTBC).

Fortunately, brand teams also have the ability to provide important information in the EHR. With today’s advanced technology, manufacturers can now add their messages to the information appearing on EHR screens. In fact, the future of enhanced EHR-enabled information flow could provide savvy manufacturers with a significant business opportunity.

In an effort to understand the potential prescribing impact of delivering in-EHR patient drug prices, ConnectiveRx recently conducted a survey of over 250 prescribers (Endocrinologists, FPs, IMs) of oral type 2 diabetes medications. Key findings appear below.

Let's talk shop.